AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) ...

Buy-now-pay-later provider Affirm says it's committed to being a remote-first company. However, one challenge of remote work is finding ways to get company culture to thrive. COO Michael Linford ...

Affirm plans to use the net proceeds to repurchase some of its 0% convertible senior notes due 2026. In addition, the company will use a portion of the net proceeds combined with cash on hand to ...

Nearly every financial institution has been evaluating generative AI, and Affirm is no exception. CEO Max Levchin teased the buy now/pay later lender's plans for generative AI deployment on the search ...

Affirm Holdings is nearing GAAP operating profitability, driven by strong gross merchandise volume growth and improving customer monetization. The expanding BNPL and e-commerce markets provide a ...